Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Reserpine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 known ✓ | Q05940 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 13/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 13/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 1.00 |
| ▸ | TSHR | P16473 | 6/20 | 1.00 |
| ▸ | HBB | P68871 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 4/20 | 1.00 |
| ▸ | CASP1 | P29466 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | CASP7 | P55210 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Reserpine SCHEMBL20402680 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL15385127 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Isoreserpine SCHEMBL731599 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL1172973 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL4562878 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL12732449 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL8262666 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL14379427 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL5372164 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL22002247 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241797-B2 | Method of increasing milk production | UNIVERSITY OF CINCINNATI (US) | 2007-07-10 | — | — | US | claimed |
| US-20030139420-A1 | Method of increasing milk production | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-24 | — | — | US | claimed |
| EP-0652767-B1 | TREATMENT OF HUMAN LACTATION FAILURE | PHARMACIA & UPJOHN AB (SE) | 1999-09-15 | — | — | EP | claimed |
| US-5276014-A | Human growth factor | KABI PHARMACIA AB (SE) | 1994-01-04 | — | — | US | claimed |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4175636-A2 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2023-05-10 | — | — | EP | disclosed |
| EP-3837229-B1 | METHOD FOR MANUFACTURING A CONSOLIDATED DENSIFIED PART FROM CERAMIC OR CARBON | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2022-06-22 | — | — | EP | disclosed |
| WO-2022006439-A2 | COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20210360924-A1 | PLANT OR SEED COATING | UNIV SOUTHAMPTON (GB) | 2021-11-25 | — | — | US | disclosed |
| EP-3837229-A1 | METHOD FOR MANUFACTURING A CONSOLIDATED DENSIFIED PART FROM CERAMIC OR CARBON | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2021-06-23 | — | — | EP | disclosed |
| WO-2020058647-A1 | METHOD FOR MANUFACTURING A CONSOLIDATED DENSIFIED PART FROM CERAMIC OR CARBON | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2020-03-26 | — | — | WO | disclosed |
| US-9012838-B2 | Covalently functionalized nanodiamond-based MALDI matrices and methods of use thereof | UNIVERSITY OF SASKATCHEWAN (CA) | 2015-04-21 | — | — | US | disclosed |
| US-20080267948-A1 | Croos-B Structure Binding Compounds | CROSSBETA BIOSCIENCES B.V. (NL) | 2008-10-30 | — | — | US | disclosed |
| US-7241797-B2 | Method of increasing milk production | UNIVERSITY OF CINCINNATI (US) | 2007-07-10 | — | — | US | disclosed |
| US-20030139420-A1 | Method of increasing milk production | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-24 | — | — | US | disclosed |
| EP-0652767-B1 | TREATMENT OF HUMAN LACTATION FAILURE | PHARMACIA & UPJOHN AB (SE) | 1999-09-15 | — | — | EP | disclosed |
| US-5276014-A | Human growth factor | KABI PHARMACIA AB (SE) | 1994-01-04 | — | — | US | disclosed |
| US-4298611-A | ADMINISTERING 2-CHLORO-6-METHYLERGOLINE-8-BETA-ACETONITRILE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1981-11-03 | — | — | US | disclosed |
| EP-0005074-A1 | A material and composition for reducing blood pressure | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1979-10-31 | — | — | EP | disclosed |
| EP-0005057-A1 | A material and composition for reducing blood pressure | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1979-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080267948-A1 | Croos-B Structure Binding Compounds | CACYBP, TBCB, MYCBP | SLC18A2 2613/4885MEN1 4546/4885KMT2A 4555/4885 |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | ALDH1A2, PDE6D, PDE6C | SLC18A2 916/4885MEN1 4843/4885KMT2A 1905/4885 |
| US-20210360924-A1 | PLANT OR SEED COATING | PNMT, TPH1, TPH2 | SLC18A2 49/4885MEN1 3232/4885KMT2A 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.